{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T09:26:22Z","timestamp":1787390782103,"version":"build-2736575974"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clon.2026.104287","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T06:52:27Z","timestamp":1782975147000},"page":"104287","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cancer Vaccines: Towards Precision Immuno-Oncology"],"prefix":"10.1016","volume":"57","author":[{"given":"A.","family":"Vitiello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Zovi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2026.104287_bib1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"issue":"7662","key":"10.1016\/j.clon.2026.104287_bib2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.clon.2026.104287_bib3","first-page":"143","article-title":"Personalized mRNA cancer vaccine in melanoma: phase 2b results","volume":"388","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clon.2026.104287_bib4","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1172\/JCI80009","article-title":"Therapeutic cancer vaccines","volume":"125","author":"Melief","year":"2015","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.clon.2026.104287_bib5","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nri.2017.131","article-title":"Towards personalized, tumour-specific, therapeutic vaccines for cancer","volume":"18","author":"Hu","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.clon.2026.104287_bib6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12916-016-0623-5","article-title":"Cancer immunotherapy: the beginning of the end of cancer?","volume":"14","author":"Farkona","year":"2016","journal-title":"BMC Med"},{"issue":"4","key":"10.1016\/j.clon.2026.104287_bib7","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ccell.2020.07.013","article-title":"Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors","volume":"38","author":"Leko","year":"2020","journal-title":"Cancer Cell"},{"issue":"6382","key":"10.1016\/j.clon.2026.104287_bib8","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.clon.2026.104287_bib9","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.18632\/oncotarget.2980","article-title":"PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma","volume":"6","author":"Luke","year":"2015","journal-title":"Oncotarget"},{"issue":"6382","key":"10.1016\/j.clon.2026.104287_bib10","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1126\/science.aar7112","article-title":"Personalized vaccines for cancer immunotherapy","volume":"359","author":"Sahin","year":"2018","journal-title":"Science"},{"issue":"7528","key":"10.1016\/j.clon.2026.104287_bib11","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature13988","article-title":"Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens","volume":"515","author":"Gubin","year":"2014","journal-title":"Nature"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S093665552600258X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S093665552600258X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T08:55:47Z","timestamp":1787388947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S093665552600258X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":11,"alternative-id":["S093665552600258X"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2026.104287","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer Vaccines: Towards Precision Immuno-Oncology","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2026.104287","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Royal College of Radiologists. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104287"}}